TY  - JOUR
AU  - Rosdah, AA
AU  - Holien, JK
AU  - Delbridge, LMD
AU  - Dusting, GJ
AU  - Lim, SY
Y2  - 2020/12/21
Y1  - 2016/06/01
SN  - 2052-1707
UR  - http://hdl.handle.net/11343/256671
AB  - Mitochondria are morphologically dynamic organelles constantly undergoing processes of fission and fusion that maintain integrity and bioenergetics of the organelle: these processes are vital for cell survival. Disruption in the balance of mitochondrial fusion and fission is thought to play a role in several pathological conditions including ischemic heart disease. Proteins involved in regulating the processes of mitochondrial fusion and fission are therefore potential targets for pharmacological therapies. Mdivi-1 is a small molecule inhibitor of the mitochondrial fission protein Drp1. Inhibiting mitochondrial fission with Mdivi-1 has proven cytoprotective benefits in several cell types involved in a wide array of cardiovascular injury models. On the other hand, Mdivi-1 can also exert antiproliferative and cytotoxic effects, particularly in hyperproliferative cells. In this review, we discuss these divergent effects of Mdivi-1 on cell survival, as well as the potential and limitations of Mdivi-1 as a therapeutic agent.
LA  - English
PB  - JOHN WILEY & SONS LTD
T1  - Mitochondrial fission - a drug target for cytoprotection or cytodestruction?
DO  - 10.1002/prp2.235
IS  - Pharmacology Research and Perspectives
VL  - 4
IS  - 3
L1  - /bitstream/handle/11343/256671/PMC4876145.pdf?sequence=1&isAllowed=y
ER  -